[Effect of blood-activating and stasis-removing drugs on hypercoagulability data in nephrotic syndrome].
Platelet aggregation test (PAgT), plasma factor VIII related antigen (VIII R:Ag) and kaolin partial thromboplastic time (KPTT) in 32 nephrotic children were determined.


RESULTS
(1) PAgT induced by ADP and adrenaline which included 1 minute and 5 minute aggregation rate in the patients (30. 78 +/- 7.44%, 72.56 +/- 18.09%, 22.16 +/- 9.24%, 67.53 +/- 22.32%) was significantly increased (P less than 0.02-0.001) as compared with the normal control group (30.65 +/- 8.38%, 57.98 +/- 13.60%, 18.14 +/- 7.33%, 55.92 +/- 16.10%) except 1 minute aggregation rate induced by ADP (P greater than 0.05). (2) VIII R:Ag and KPTT in patients (226.97 +/- 50.47%, 32.04 +/- 5.88 sec) were obviously different (P less than 0.001, P less than 0.02) from the normal control group (107.11 +/- 24.55%, 35.42 +/- 5.00 sec). The results suggested that PAgT, VIII R:Ag and KPTT could be used as laboratory data reflecting the hypercoagulable state in nephrotic children. According to their age, sex and the clinical types of nephrotic syndrome, 24 nephrotic children with abnormality of PAgT, VIII R:Ag and KPTT were random divided into group 1 given prednisone only and group 2 given prednisone, blood-activating and stasis-removing drugs.


RESULTS
the difference of PAgT, VIII R:Ag and KPTT in two groups between pre- and post-treatment was significant statistically (P less than 0.05-P less than 0.001). The decline in PAgT and VIII R:Ag was faster in group 2 than in group 1 (P less than 0.05-P less than 0.01). The results showed that blood-activating and stasis-removing drugs were likely to improve abnormal PAgT and VIII R:Ag in nephrotic children.
Wu
Q
Q
Children's Hospital, Shanghai Medical University.
Gu
W
W
D002648:Child; D002675:Child, Preschool; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy*; D010314:Partial Thromboplastin Time; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D014841:von Willebrand Factor / Q000032:analysis
D004365:Drugs, Chinese Herbal; D010975:Platelet Aggregation Inhibitors; D014841:von Willebrand Factor